In the IO space, the anti-NKG2A monalizumab and the anti-CD73 oleclumab have been evaluated in locally advanced NSCLC in combination with durvalumab after chemoradiotherapy in stage III NSCLC (77). The gene discussed is KLRC1; the disease is non-small cell lung carcinoma.